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Expression, regulation and clinical relevance of the ATPase
inhibitory factor 1 in human cancers
M Sa´nchez-Arago´1,6, L Formentini1,6, I Martı´nez-Reyes1, J Garcı´a-Bermudez1, F Santacatterina1, L Sa´nchez-Cenizo1, IM Willers1,
M Aldea1, L Na´jera2, A´ Juarra´nz3, EC Lo´pez1, J Clofent4, C Navarro4, E Espinosa5 and JM Cuezva1
Recent ﬁndings in colon cancer cells indicate that inhibition of the mitochondrial Hþ -adenosine triphosphate (ATP) synthase by the
ATPase inhibitory factor 1 (IF1) promotes aerobic glycolysis and a reactive oxygen species (ROS)-mediated signal that enhances
proliferation and cell survival. Herein, we have studied the expression, biological relevance, mechanism of regulation and potential
clinical impact of IF1 in some prevalent human carcinomas. We show that IF1 is highly overexpressed in most (490%) of the colon
(n¼ 64), lung (n¼ 30), breast (n¼ 129) and ovarian (n¼ 10) carcinomas studied as assessed by different approaches in independent
cohorts of cancer patients. The expression of IF1 in the corresponding normal tissues is negligible. By contrast, the endometrium,
stomach and kidney show high expression of IF1 in the normal tissue revealing subtle differences by carcinogenesis. The
overexpression of IF1 also promotes the activation of aerobic glycolysis and a concurrent ROS signal in mitochondria of the lung,
breast and ovarian cancer cells mimicking the activity of oligomycin. IF1-mediated ROS signaling activates cell-type speciﬁc
adaptive responses aimed at preventing death in these cell lines. Remarkably, regulation of IF1 expression in the colon, lung, breast
and ovarian carcinomas is exerted at post-transcriptional levels. We demonstrate that IF1 is a short-lived protein (t1/2 B100min)
strongly implicating translation and/or protein stabilization as main drivers of metabolic reprogramming and cell survival in these
human cancers. Analysis of tumor expression of IF1 in cohorts of breast and colon cancer patients revealed its relevance as a
predictive marker for clinical outcome, emphasizing the high potential of IF1 as therapeutic target.
Oncogenesis (2013) 2, e46; doi:10.1038/oncsis.2013.9; published online 22 April 2013
Subject Categories: cancer metabolism
Keywords: Hþ -ATP synthase; ATPase inhibitory factor 1; energy metabolism; mitochondria; cancer prognosis; ROS signaling
INTRODUCTION
Downregulation of oxidative phosphorylation and concurrent
activation of aerobic glycolysis is a hallmark feature of pro-
liferating cells and of many different human carcinomas.1–3
An enhanced aerobic glycolysis provides the metabolic inter-
mediates required to sustain proliferation.1,4 Several genetically-
driven mechanisms directly promoting glycolysis, the inhibition of
mitochondrial function or both have been proposed in order to
explain energy metabolism in cancer cells and tumors (for review
see Cuezva et al.1 and Cairns et al.5). Moreover, it has been
suggested that the APC/C–Cdh1 complex that controls the
levels of PFKFB3, and hence, the rate of glucose consumption
might participate in sustaining glycolysis in some types of
human carcinomas.6 However, epigenetic mechanisms7,8 and
the tumor microenvironment5,9 also have relevant roles in
cancer development and progression by regulating the
bioenergetic phenotype of cancer cells.10
The Hþ -adenosine triphosphate (ATP) synthase is a master
regulator of energy metabolism and cell fate. It is the mitochon-
drial protein complex of oxidative phosphorylation that catalyzes
the synthesis of ATP using as driving force the proton gradient
generated by the respiratory chain.11 The Hþ -ATP synthase is
also required for efﬁcient execution of cell death.12,13 In fact, cells
that are unable to perform oxidative phosphorylation have
an apoptotic-resistant phenotype.13–15 Conversely, activation of
the bioenergetic function of mitochondria prevents tumor
development.16,17
A compromized bioenergetic activity of mitochondria, as
assessed by genomic,18 transcriptomic,10 proteomic1,19 and
functional studies,20 is involved in tumor progression and in
chemotherapeutic resistance.21–24 Speciﬁcally, it has been
described: (i) the downregulation of the cellular abundance of
the mRNAs that encode rate-limiting subunits of the Hþ -ATP
synthase by either promoter hypermethylation of the ATP5B
gene23 or by genetic deletion of ATP5A118; (ii) the masking of the
translation of b-F1-ATPase mRNA25,26 through the binding of
repressor proteins27 that impede ribosome recruitment and
translation and (iii) the overexpression in cancer cells and
tumors of the ATPase inhibitory factor 1 (IF1) that inhibits the
activity of the mitochondrial Hþ -ATP synthase.28 Furthermore,
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recent ﬁndings indicate that IF1 has additional functions in colon
cancer cells by promoting a reactive oxygen species (ROS)-
mediated adaptive cellular response that triggers proliferation and
resistance to cell death.29
In this investigation, we have addressed (i) the study of
the expression level of IF1 in different prevalent human
carcinomas, (ii) the metabolic and signaling events that mediate
IF1 overexpression in the lung, breast and ovarian cancer cells,
(iii) the mechanisms that mediate IF1 overexpression in tumors
and (iv) its relevance as a prognostic marker in breast and
colon cancer patients. Overall, the results indicate that IF1 has a
very short half-life being highly overexpressed in the colon,
lung, breast and ovarian carcinomas by mechanisms that are
regulated at post-transcriptional levels. In contrast, normal
tissues that overexpress IF1, such as endometrium and kidney,
reveal no relevant changes in IF1 triggered by carcinogenesis.
The overexpression of IF1 promotes the activation of aerobic
glycolysis and concurrently confers a ROS-mediated resistance
to staurosporine (STS)-induced cell death to the lung, breast
and ovarian cancer cells. Moreover, the tumor expression of
IF1 is a predictive marker for clinical outcome in breast and colon
cancer patients. As IF1 masters the reprogramming of energy
metabolism and signals cell-death resistance in cancer cells, we
suggest that IF1 offers a relevant molecule with high potential as a
new therapeutic target for treatment of prevalent human
carcinomas.
RESULTS
IF1 is overexpressed in most prevalent human carcinomas
Western blots in Figure 1 illustrate that the monoclonal antibody28
recognizes the recombinant, as well as the two major isoforms
(B12 and B8 kDa) of native IF1 in normal human liver and
stomach extracts (Figure 1). The expression of IF1 is negligible in
the normal breast, colon and lung (Figure 1), but sharply increases
in their corresponding carcinomas (Figure 1). Colon carcinomas
also express the shortB8 kDa IF1 isoform (Figure 1). Interestingly,
normal stomach shows a high expression of IF1 and revealed no
relevant changes by carcinogenesis (Figure 1). It should be noted
that heart (not shown) and liver (Figure 1) are the normal human
tissues with highest expression of IF1.
The expression of IF1 was also assessed by immunohisto-
chemistry in a different cohort of normal human tissues and
carcinomas (Figure 2). Consistent with western blot data (Figure 1),
immunohistochemistry of cancer tissue microarrays conﬁrmed
that the expression of IF1 is negligible in the normal colon,
lung, breast and ovary (Figure 2). In contrast, carcinomas in
these tissues showed a highly signiﬁcant increase in the granular
cytoplasmic immunostaining of IF1 (Figure 2). Contrary to
these ﬁndings, the expression of IF1 in normal epithelial cells of
the endometrium and kidney was very high (Figure 2) and its
content did not show signiﬁcant changes by carcinogenesis
(Figure 2).
Figure 1. Expression of human IF1 in normal and tumor tissues. Western blots reveal the expression of IF1 (h-IF1) in SDS–polyacrylamide
gel electrophoresis fractionated proteins from normal (N) and tumor (T) biopsies of different human tissues. The antibody recognizes
the recombinant protein, as well as the two major 12- and 8-kDa protein isoforms of IF1. b-actin expression is shown as loading control.
For comparison purposes, the expression level of IF1 in human tissues (histograms) is normalized relative to its expression in HeLa cells
(a.u., arbitrary unit) assayed in the same blot. The number of paired normal and tumor biopsies analyzed is indicated in parenthesis.
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Post-transcriptional regulation of IF1 expression in cancer
Details on the analysis of the promoter region of the human IF1
gene (ATPIF1) and its possible relationship with the expression of
hypoxia-inducible factor-1a30 are provided in Supplementary
Figure S1 and Supplementary Figure S2, respectively. In any case,
the cellular availability of IF1 mRNA was not signiﬁcantly different
in the colon, lung and breast carcinomas when compared with
that in the corresponding normal tissues (Figure 3a). Moreover, IF1
mRNA was signiﬁcantly reduced in ovarian carcinomas (Figure 3a).
The immediate early response gene (IER3) has been shown to
target IF1 for degradation by a mitochondrial protease.31 Studies
aimed at characterizing the relevance of protein stability in the
expression of IF1 in colon cancer cells revealed a very rapid
accumulation of the protein in response to the serine-protease
inhibitor 4-(2-aminoethyl) benzenosulfonyl ﬂuoride hydrochloride
(Figure 3b), suggesting the participation of either the ATP-
dependent Lon protease or ClpXP32 in the degradation of IF1.
The short half-life of IF1 was further demonstrated by pulse-chase
experiments (Figure 3c) that indicated a t1/2 for the protein
ofB100min. Overall, these ﬁndings indicate the relevance of
translational and post-translational regulatory mechanisms for the
expression of IF1 in cancer.
Analysis of the expression of IER3 in the lung, breast and colon
carcinomas revealed that it is overexpressed in 16 out of the 18
carcinomas analyzed (Supplementary Figure S3A). Moreover, partial
silencing of the protein in colon cancer cells revealed no relevant
effect on the expression of IF1 (Supplementary Figure S3B), what
suggests that degradation of IF1 is a complex process.
Figure 2. IF1 is upregulated in some prevalent human carcinomas. Representative immunohistochemistries of IF1 expression in normal
and tumor tissue of the colon, lung, breast, ovary, endometrium and kidney. Magnification  20,  40 and  63. Histograms to the right of
the pictures show the quantification of IF1 expression in normal (N, green, n¼ 5) and tumor (T, red, n¼ 10) specimens expressed as arbitrary
units (a.u.). The results shown are the mean±s.e.m. *Po0.05 when compared with normal by Student’s t-test. Note that whereas normal
epithelial cells from the colon, lung, breast and ovary show low or negligible expression of IF1, endometrial and kidney cells have very-high
expression of IF1.
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IF1 regulates energy metabolism in the lung, breast and ovarian
cancer cells
Consistent with previous reports in colon cancer cells,29 the
overexpression of IF1 in the lung, breast and ovarian cancer cells
promoted a signiﬁcant increase in the rates of aerobic glycolysis
(Figure 4a). The increase in glycolysis was similar to that exerted
by incubation of the cells with oligomycin, a pharmacological
inhibitor of the Hþ -ATP synthase (Figure 4a). Conversely, small
interfering RNA-mediated silencing of IF1 promoted a signiﬁcant
reduction in the rates of glycolysis in most cancer cells except in
HOP62 (Figure 4a). The expression of IF1 varies largely between
cancer cells (Figure 4b), whereas the basal rates of aerobic
glycolysis were found to be quite similar (Figure 4a), indicating
that glycolysis is regulated by other factors in addition to the
expression level of IF1.33
IF1 overexpression generates a mitochondrial ROS signal in the
lung, breast and ovarian cancer cells
The overexpression of IF1 in the lung, breast and ovarian cancer
cells promoted a signiﬁcant increase in the production of
superoxide radical (Figure 5). The mitochondrial scavenger MitoQ
(MQ)34 was able to quench the production of superoxide in all cell
lines studied (Figure 5), supporting the role of IF1 as a general
ROS-mediating signaling molecule in mitochondria.29 We should
mention that the IF1-mediated ROS signal generated in
mitochondria is of mild intensity because neither the cellular
hydrogen peroxide levels nor the GSH/GSSG ratio have been
found to be altered by IF1 overexpression.29
In sharp contrast with the ﬁndings in colon cancer cells,29 the
IF1-mediated ROS signal was unable to stimulate cellular
proliferation as assessed by the incorporation of 5-ethynyl-20-
deoxyuridine (EdU) into cellular DNA in the lung, breast and
ovarian cancer cells (Supplementary Figure S4).
Mitochondrial ROS protect the lung, breast and ovarian
carcinomas from STS-induced cell death
The IF1-mediated ROS signal was able to protect the lung, breast
and ovarian cancer cells from STS-induced cell death (Figure 6).
Quenching the ROS signal with MQ prevented protection against
STS-induced cell death (Figure 6). Interestingly, we observed that
the intensity of the ROS-mediated response to IF1 overexpression
(Figure 5) correlated with the degree of protection against
Figure 3. IF1 expression is regulated at post-transcriptional levels. (a) The colon (HCRT103), lung (HLRT104), breast (BCRT101) and ovarian
(HORT102) TissueScan Tissue quantitative PCR Arrays were used to determine the expression of IF1 mRNA in different normal (open bars) and
tumor (closed bars) tissue specimens. The number of studied patients is indicated in brackets. The results shown are the mean±s.e.m.
*Po0.001 when compared with normal by Student’s t-test. (b) HCT116 cells were treated with 400 mM of the serine-proteases inhibitor
4-(2-aminoethyl) benzenosulfonyl fluoride hydrochloride for the indicated time and the expression of IF1 and b-actin (loading control)
analyzed by western blot. Lanes 1 and 2, show different experiments of the same condition. Bars are the mean±s.e.m. of four experiments.
*Po0.05 when compared with 0 h by Student’s t-test. (c) After metabolic labeling with 35S-methionine IF1 was immunoprecipitated from
HCT116 cells at the indicated time. Lanes 1 and 2, show different experiments of the same condition of the chase. The fluorogram reveals the
migration of both the precursor and mature IF1 (arrow) 35S-labeled immunoprecipitated proteins. The plot shows the first order rate kinetics
of the decay of IF1. The t1/2 for IF1 is in the 105–120min range.
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Figure 4. IF1 regulates the activity of aerobic glycolysis in the lung (HOP62, A549), breast (BT549, HS578T) and ovarian (OVCAR8, OVCAR3)
cancer cells. (a) Cells transfected with CDL-GFP-b-30UTR were co-transfected with control (CRL and siCRL, open bars), IF1 plasmid (IF1þ , dark
gray bars) or siIF1 small interfering RNA (siIF1, light gray bars) to regulate the expression of IF1 for the determination of the rates of aerobic
glycolysis. The effect of 6 mM oligomycin (OL, closed bars) is shown. Representative blots of IF1 and b-F1-ATPase (b-F1) expression. Bars are the
mean±s.e.m. of six different samples. *Po0.05 when compared with CRL by Student’s t-test. (b) IF1 (h-IF1) expression in 20mg of protein from
different human cell lines. Two different exposures of the IF1 film are presented. b-actin expression is shown as loading control.
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STS-induced cell death (plot in Figure 6), suggesting a relevant
role for mitochondrial ROS signaling in promoting survival
pathways in all cancer cells.
For instance, and in support of this idea, transcriptional activity
of the nuclear factor kappa-light-chain-enhancer of activated B
cells (NFkB) promoter in the lung, breast and ovarian carcinomas
was greatly enhanced by IF1 overexpression (Figure 7a) and
partially quenched by the mitochondrial ROS scavenger MQ
(Figure 7a). The ROS-mediated activation of the NFkB pathway in
HOP62 lung cancer cells is supported by a reduction in the
expression of the NFkB repressor IkBa (nuclear factor of kappa
light polypeptide gene enhancer in B-cells inhibitor, alpha) and
the concurrent increase in the expression of the antiapoptotic
Bcl-xL (Figure 7b). These changes were partially reversed by the
mitochondrial ROS scavenger MQ (Figure 7b). However, the same
studies in breast (BT549, HS578T) and ovarian (OVCAR8) cancer
cells did not provided similar ﬁndings (data not shown)
emphasizing the complexity of the survival pathways that are
activated in cancer cells in response to mitochondrial ROS
signaling.
Clinical relevance of IF1 in breast cancer
A next question was to assess the potential relevance of IF1 in the
clinics. We determine the expression level of IF1 in a cohort of
tumors of breast cancer patients operated from invasive
carcinomas for which the bioenergetic signature or bioenergetic
cellular index (b-F1-ATPase/Hsp60/GAPDH ratio) and follow-up
information is available.35,36 The results in Supplementary Table S1
summarize the clinicopathological characteristics of the cohort of
patients studied and the expression level of IF1 in the carcinomas
according to the clinical information. It should be noted that the
expression of IF1 in normal breast biopsies was negligible (Figures
1 and 2). Although the tumor expression of IF1 did not show
signiﬁcant differences between patients with clinical-pathological
markers relevant for tumor progression, such as nodal involve-
ment, tumor size and histological grade (Supplementary Table S1),
it was signiﬁcantly diminished in the poor prognosis groups of
lobular and hormone receptor negative carcinomas when
compared with ductal and hormone receptor positive carcinomas,
respectively (Supplementary Table S1).
From the molecular point of view, the expression of IF1
inversely correlated with the bioenergetic cellular index35 of the
tumors (R¼  0.437; P¼ 0.0001), suggesting that the increased
expression of IF1 parallels the program of repression of the
bioenergetic activity of mitochondria in cancer cells. Surprisingly,
Kaplan–Meier survival analysis revealed that a low tumor
expression of IF1 predicted a higher rate for disease-recurrence
in breast cancer patients (Figure 8a).
Clinical relevance of IF1 in colon cancer
Next, we determine the quantity of IF1 in normal and tumor
biopsies in a cohort of colon cancer patients in which the markers
of energy metabolism have been previously quantiﬁed.37
The amount of IF1 was determined using reverse phase
Figure 5. IF1 regulates mitochondrial ROS production in the lung (HOP62, A549), breast (BT549, HS578T) and ovarian (OVCAR8, OVCAR3)
cancer cells. Cells transfected with CDL-GFP-b-30UTR were co-transfected with control (CRL, open and light gray bars) or IF1 plasmid (IF1, dark
gray and closed bars) in the absence or presence (þMQ) of 5 nM of the mitochondrial ROS scavenger MitoQ (MQ). The superoxide radical was
determined by fluorescence-activated cell sorting analysis using MitoSox. The data shown are mean±s.e.m. of 12 different samples. *Po0.05
and #Po0.05 when compared with CRL or IF1 by Student’s t-test, respectively.
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protein microarrays (Supplementary Figure S5).37 The results in
Supplementary Table S2 summarize the clinicopatho-
logical characteristics of the cohort of patients studied and the
quantity of IF1 in the carcinomas according to the clinical
information. Colon carcinomas showed a signiﬁcant twofold
increase in the amount of IF1 when compared to normal colon
biopsies (Supplementary Table S2). The tumor content of IF1
did not show signiﬁcant differences between patients with
clinical-pathological markers relevant for tumor progression
(Supplementary Table S2).
In colon cancer, the expression of IF1 also inversely correlated
with the bioenergetic cellular index37 of the tumors (R¼  0.526;
P¼ 0.001), once again suggesting that the increased expression of
IF1 in colon cancer cells parallels the program of metabolic
reprogramming experienced by these carcinomas. Kaplan–Meier
survival analysis also revealed that a low tumor expression of IF1
predicted a worst overall prognosis for colon cancer patients
(Figure 8b).
DISCUSSION
We show that IF1 is highly overexpressed in all human carcinomas
of the colon, lung, breast and ovary showing negligible expression
in their corresponding normal tissues. IF1 promotes the activation
of aerobic glycolysis and generates a concurrent ROS signal in mito-
chondria that activates cell-type speciﬁc adaptive responses aimed
at preventing death in the lung, breast and ovarian cancer cells.
Mechanistically, IF1 mimics the effects of oligomycin, an inhibitor of
the Hþ -ATP synthase.13,29 Remarkably, we show that the regulation
of the expression of IF1 in carcinomas of the colon, lung, breast and
ovary is exerted at post-transcriptional levels. In fact, we
demonstrate that IF1 is a short-lived protein that is degraded by
mitochondrial serine-proteases. Overall, we provide the ﬁrst
demonstration supporting that regulation of the synthesis and/or
degradation of a mitochondrial protein involved in the control of
oxidative phosphorylation has a master role in metabolic rewiring
and in signaling cell-death resistance in prevalent human
carcinomas. Moreover, we show that IF1 expression has relevance
as a predictive marker for clinical outcome in breast and colon
cancer patients.
The expression level of IF1 varies greatly within normal human
tissues. Consistent with the role of IF1 as inhibitor of the Hþ -ATP
synthase,28,29 a high expression of IF1 in normal tissues such as
heart, liver and kidney would imply the partial mass-action-
mediated inhibition of oxidative phosphorylation and thus a
limitation in cellular ATP availability. This situation is obviously not
possible because these tissues have a very-high metabolic
demand. Thus, our ﬁndings suggest that in addition to the well
characterized pH regulated binding of IF1 to the Hþ -ATP
synthase,38 a mechanism should exist in tissues with high
metabolic demand to promote the mass-action-mediated
inhibition of IF1 on the Hþ -ATP synthase activity.28 In this
Figure 6. IF1 regulates the cell-death response in the lung (HOP62, A549), breast (BT549, HS578T) and ovarian (OVCAR8) cancer cells. Cells
transfected with CDL-GFP-b-30UTR were co-transfected with control (CRL, open and light gray bars) or IF1 plasmid (IF1, dark gray and closed
bars) in the absence or presence (þMQ) of 5 nM of the mitochondrial ROS scavenger MitoQ (MQ). Twenty-four hours after transfection, the
cells were treated with 1mM STS and 24h later the cells were stained with propidium iodide and the green population of cells was analyzed by
flow cytometry to evaluate the percentage of sub-G0 cells. The data shown are mean±s.e.m. of six–nine different samples. *Po0.05
and #Po0.05 when compared with CRL or IF1 by Student’s t-test, respectively. The plot shows the linear correlation that exists between the
IF1-mediated ROS-response and the observed cell death.
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regard, it has been described that IF1 also binds other membrane
proteins of mitochondria in a pH and DCm independent
manner39,40 hampering its activity as an inhibitor of the
ATPase.40 Alternatively, potential tissue-speciﬁc post-translational
modiﬁcations of IF1 could explain the differential activity exerted
by IF1 in different human tissues.
At variance with other mitochondrial proteins41 we show that
IF1 is a short-lived protein with a turnover in the range of minutes.
This ﬁnding is of utmost importance to understand the
bioenergetic activity of mitochondria. In fact, a rapid turnover of
the protein would allow cells to quickly adapt the output of ATP
by oxidative phosphorylation to changing physiological cues. One
can speculate that mutations in cancer genes or other epigenetic
events of the tumor microenvironment switch-on the mechanisms
that promote a high expression of IF1 in the tumor. We suggest
that an increase in translation of IF1 mRNA and/or in the stability
of the protein should occur in human carcinomas to provoke the
overwhelming expression of IF1 observed in these tumors. The
Figure 7. IF1 triggers transcriptional activation of the NFkB promoter in the lung (HOP62), breast (BT549) and ovarian (OVCAR8) cancer cells.
Cells transfected with CDL-GFP-b-30UTR were co-transfected with control (CRL, open and light gray bars) or IF1 (IF1, dark gray or closed bars)
plasmid in the absence or presence (þMQ) of 5 nM of the mitochondrial ROS scavenger MitoQ (MQ). (a) A luciferase reporter plasmid of the
NKkB promoter was co-transfected and the luciferase activity was determined in cellular extracts after 24-h transfection. The data shown are
mean±s.e.m. of 10 samples. *Po0.05 and #Po0.05 when compared with CRL or IF1 by Student’s t-test, respectively. (b) Cellular proteins of
HOP62 were fractionated on SDS–polyacrylamide gel electrophoresis and processed for western blotting with the indicated primary
antibodies. Representative blots are shown. The results are mean±s.e.m. of three experiments. *Po0.05 and #Po0.05 when compared with
CRL or IF1 by Student’s t-test, respectively.
Figure 8. Kaplan–Meier survival analyses reveal the clinical relevance of IF1. (a) Protein samples from breast tumor biopsies were analyzed by
western blot for the expression level of IF1. Kaplan–Meier disease-free survival analysis for 93 breast cancer patients stratified by the tumor
expression level of IF1. The plot shows a significant association of low IF1 expression with a poor outcome for the patients. The log-rank test
P-value is shown. (b) Protein samples from normal and tumor biopsies from a cohort of patients with colorectal cancer were analyzed by
reverse phase protein microarrays to quantify IF1 (see Supplementary Figure S4). Kaplan–Meier overall survival analysis for 38 colon cancer
patients stratified by the tumor quantity of IF1. The plot shows a significant association of low IF1 expression with a poor outcome for the
patients. The log-rank test P-value is shown.
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control of IF1 translation is presently unknown and it might
involve regulatory proteins and microRNAs as we have shown for
b-F1-ATPase mRNA.27,42,43
IER3 gene has been shown to suppress ROS production and to
render IF1 prone to proteolytic digestion.31 Paradoxically, and in
contrast with ﬁndings in ovarian44 and pancreatic45 cancer our
results indicate that IER3 is overexpressed in the lung, breast and
colon cancer. Moreover, we found no correlation between IER3
and IF1 expression suggesting that the control of the degradation
of IF1 is more complex than originally anticipated and that the
participation of IER3 might depend on the cell-type analyzed. An
alternative explanation for the accumulation of IF1 in carcinomas
could be the partial inactivation of the mitochondrial serine-
protease involved in its turnover. In this regard, the Lon protease
has been reported to diminish its activity during ageing.46
Moreover, cancer cells exhibit high basal levels of oxidative
stress5 and the Lon protease is particularly vulnerable to
inactivation by ROS.47 The implication of ClpXP in human
pathology is scant despite its relevance in the degradation of
proteins involved in metabolic reprogramming.48 As previously
discussed, potential oncogene- and/or metabolic-driven post-
translational modiﬁcations of IF1 could also explain its
accumulation in carcinomas if such changes hamper the
mitochondrial pathway of IF1-degradation.
Despite the large structural and molecular differences of
mitochondria in mammalian cells,49 but consistent with previous
ﬁndings in colon cancer,29 we show that the IF1-mediated
inhibition of the Hþ -ATP synthase switches on aerobic glycolysis
and generates a mitochondrial ROS signal in all cancer cells
studied. Mitochondrial ROS signaling represents a pathway of
retrograde communication to the nucleus of the cell that
inﬂuences adaptive cellular responses.50 The results herein
indicate that whereas mitochondrial ROS signaling triggers
protection against cell death in all cellular types studied, it is
unable to stimulate proliferation in the lung, breast and ovarian
carcinomas, what is at variance with colon cancer cells.29 These
ﬁndings indicate the existence of common and cell-type speciﬁc
programs of nuclear response to mitochondrial ROS signaling. The
effect of ROS on the cellular response depends on the level51 and
site52 at which they are being produced. Moreover, ROS interact
with diverse signaling pathways being transcription factor NFkB, a
crucial regulator of adaptive responses related with survival.53,54 In
colon cancer cells, IF1 mediated the activation of the canonical
NFkB pathway of survival.29 The results herein support that
although IF1 is able to trigger the ROS-mediated transcriptional
activation of the NFkB promoter as a common response to the
lung, breast and ovarian cancer cells, only lung carcinomas seem
to activate the same NFkB-mediated survival pathway. These
results emphasize the critical function that NFkB has in signaling
lung tumor development, in agreement with previous ﬁndings in
a mouse model of lung carcinogenesis,55 and highlight the need
of speciﬁc studies aimed at unveiling the IF1-mediated pathways
of survival that are activated in breast and ovarian cancer cells.
Redox regulation has an essential role in malignancies29,56,57
but the mechanisms of its actions and its impact in tumor
prognosis remain unclear. Contrary to what would be expected for
an oncogenic protein,58 we found that breast and colon cancer
patients with high tumor expression of IF1 have a better
prognosis. There are other examples in the literature illustrating
similar paradoxes. For instance, miR-200s that modulate the
oxidative stress response increase tumor growth in mouse
models.59 However, a high expression of miR-200s is linked to a
favorable prognosis,60 whereas downregulation of miR-200s is
associated with relapse in patients with ovarian cancer.61 Similarly,
isocitrate dehydrogenase mutations are paradoxically associated
with better survival in glioma patients.62 As a low expression of IF1
in carcinomas predicts a shorter time for relapse or death of the
patient, we suggest that cells with low expression of IF1 are more
likely to metastasize. In this regard, it is possible that cells with
high expression of IF1, which have a low bioenergetic signature
become more vulnerable to metabolic or other forms of stress
during detachment and/or become more easily recognized by the
immune system.2 Indeed, cells with a low bioenergetic signature
are addicted to glucose and are more sensitive to glucose
deprivation and the inhibition of glycolysis.24,63
Overall, we document that the short-lived inhibitor of the
mitochondrial Hþ -ATP synthase is overexpressed in the colon,
lung, breast and ovarian cancer mastering the reprogramming of
energy metabolism and signaling a cell-death resistance pheno-
type. Moreover, we support its potential as a marker of clinical
outcome in breast and colon cancer patients. We stress that
speciﬁc studies and animals models are needed to unveil the
molecular and cellular biology of IF1 in the different cell types of
mammals.
MATERIALS AND METHODS
Patient specimens and protein extraction
Frozen tissue obtained from surgical specimens of untreated cancer
patients with primary adenocarcinomas of the breast, colon, stomach,
kidney and lung were obtained from the Banco de Tejidos y Tumores,
IDIBAPS (Instituto de Investigaciones Biome´dicas Pi y Sun˜er), Hospital
Clinic, Barcelona, Spain.64 A collection of frozen tissue sections obtained
from surgical specimens of (i) ninety-three patients who had an operation
for invasive breast carcinoma at the Hospital Universitario La Paz between
1991 and 200035,36 and (ii) of untreated cancer patients with primary
colorectal adenocarcinomas enrolled in the incident Spanish CRC Epicolon
Study and prospectively followed during 5 years37,65 obtained from the
Banco de Tejidos y Tumores, Hospital Meixoeiro, Vigo, Spain were also
used (see Supplementary Information for Bioethic details).
Cell cultures, treatments, transfections and small interfering RNA
silencing
The Human cervical (HeLa), breast (HS578T, NCI-ADR-RES, BT549, MCF12),
lung (A549, HOP62), colon (KM12, HCT116) and ovarian (OVCAR8,
OVCAR 3) cells were grown following the suppliers´ instructions. When
needed, cells were left untreated or treated with 200mM CoCl2 (Sigma-
Aldrich, St Louise, MO, USA) for 6 h. For inhibition of mitochondrial serine-
proteases HCT116 cells were treated with 400mM of 4-(2-aminoethyl)
benzenosulfonyl ﬂuoride hydrochloride for the indicated time. Transfection
and silencing experiments were performed as recently described.29
Protein fractionation and western blots
Cell lysis and protein fractionation were carried out as described.27 The
primary antibodies used were: anti-b-actin (Sigma-Aldrich, 1:20000), anti-b-
F1-ATPase (Acebo et al.66 1:20000), anti-IkBa and anti-Bcl-xL (Cell Signaling
Technology, Inc., Danvers, MA, USA, 1:1000), anti-hypoxia-inducible factor-
1a (Santa Cruz Biotechnology Inc., Dallas, TX, USA, 1:150) and anti-IF1
(Sanchez-Cenizo et al.28 1:200).
Immunohistochemistry
Cancer Survey Tissue Microarrays (OriGene (Rockville, MD, USA)) containing
5 mm sections of formalin-ﬁxed normal and tumor specimens of the breast,
colon, lung, kidney, ovarian and endometrial tissues were immunostained
using the monoclonal anti-IF1 (1:200) antibody as previously described.19
Sections were counterstained with hematoxylin.
Quantiﬁcation of mRNA expression
Human b-F1-ATPase and IF1 mRNA levels in normal and tumor tissues
were carried out by quantitative PCR using the breast (BCRT101), ovarian
(HORT102), colon (HCRT103) and lung (HLRT104) TissueScan Tissue
quantitative PCR Arrays from OriGene Technologies, Inc. For detailed
pathological information of these patients see Supplementary Table S3.
Real-time quantitative PCR was performed as described.27 The following
forward (F) and reverse (R) primers were used to amplify human b-F1-
ATPase and IF1 cDNAs: F: 50- CAGCAGATTTTGGCAGGTG-30 , R: 50-CTTCAATG
GGTCCCACCATA-30 ; F: 50-GGGCCTTCGGAAAGAGAG-30 and R: 50-TTCAAAGC
TGCCAGTTGTTC-30 , respectively.
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Metabolic labeling and immunoprecipitation
Metabolic labeling was initiated by addition to the culture medium 0.65
mCi of [35S]-methionine/ml. Duration of the pulse was 1 h. At the indicated
time-points IF1 was immunoprecipitated from cellular lysates using
G-sepharose precoated with 12 mg of anti-IF1 IgGs.67
Quantiﬁcation of IF1 in colorectal adenocarcinoma biopsies using
reverse phase protein microarrays
IF1 was expressed and puriﬁed as detailed.28 Samples from colorectal
adenocarcinoma patients were diluted in PBS to a ﬁnal protein
concentration of 1 mg/ml before printing onto nitrocellulose-coated glass
slides (FAST Slides, Scheleicher & Schuell BioScience, Inc.) using a
BioOdyssey Calligrapher MiniArrayer printer (Bio-Rad Laboratories, Inc.,
Keene, NH, USA) as recently described.37 Arrays were incubated with anti-
IF1 (1 mg/ml) followed by incubation with a donkey anti-mouse conjugated
with alexa-488 (Life Technologies, Grand Island, NY, USA). Microarrays were
scanned using a Typhoon 9410 scanner (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ, USA). The mean ﬂuorescent intensity of the spots was
quantiﬁed using Image J software (N.I.H., USA) and converted into pg of
protein/ng of total protein using the ﬂuorescent intensity units obtained in
the respective standard curve of recombinant protein.37
Bioinformatic Search of the ATPIF1 gene
UCSC Genome Browser (http://genome.ucsc.edu/) was used. Chip-sep data
was obtained from ENCODE database.
Determination of reactive oxygen species
Where indicated, B2 105 cells were incubated overnight with 10–20 nM
of MQ. The intracellular production of superoxide radical was monitored by
ﬂow cytometry using 5 mM MitoSOX (Invitrogen) incubated 15min at
37 1C.29 Cells were analyzed in a FACScan. For each analysis 10 000 events
were recorded.
Other methods
Details for the determination of aerobic glycolysis, proliferation, cell death
and NFkB promoter activity have been recently provided.29 Where
indicated 5 nM of MQ was added to the incubation.
Statistical analysis
Distribution of molecular markers and other categorical variables were
compared by w2 and Student’s t-test. The statistical signiﬁcance of linear
regressions was assessed by Pearson’s correlation t-test. To determine the
association between the expression level of IF1 with disease-free survival
and overall survival the cutoff point used to deﬁne high- and low-risk
groups was the mean value of protein expression in normal breast or colon
samples. Survival curves were derived from Kaplan–Meier estimates and
compared by log-rank test. Statistical test were two-side at the 5% level of
signiﬁcance. All computations were carried out using SPSS, version 17.0
(IBM Corporation, Armonk, NY, USA).
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